5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.56▼ | 2.49▲ | 2.45▲ | 2.53▲ | 2.59▼ |
MA10 | 2.57▼ | 2.43▲ | 2.44▲ | 2.65▼ | 2.20▲ |
MA20 | 2.51▲ | 2.43▲ | 2.45▲ | 2.57▼ | 1.62▲ |
MA50 | 2.43▲ | 2.47▲ | 2.60▼ | 2.06▲ | 1.77▲ |
MA100 | 2.43▲ | 2.61▼ | 2.64▼ | 1.54▲ | 1.96▲ |
MA200 | 2.45▲ | 2.63▼ | 2.42▲ | 1.66▲ | 3.20▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.024▲ | 0.022▲ | -0.057▼ | 0.171▲ |
RSI | 67.031▲ | 65.267▲ | 58.695▲ | 57.322▲ | 66.326▲ |
STOCH | 55.470 | 59.028 | 47.716 | 30.488 | 91.411▲ |
WILL %R | -19.355▲ | -12.500▲ | -12.500▲ | -64.401 | -19.082▲ |
CCI | 31.670 | 181.774▲ | 206.689▲ | -73.152 | 81.666 |
Friday, September 19, 2025 07:37 AM
The Japanese Ministry of Health, Labour and Welfare has approved NEXLETOL (bempedoic acid) tablets for the treatment of hypercholesterolemia and familial hypercholesterolemia, according to a statement ...
|
Friday, September 19, 2025 05:25 AM
Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL ® (bempedoic acid) tablets in Japan, ...
|
Sunday, September 07, 2025 07:17 PM
Discover Esperion's growth, new cardiovascular drugs, global expansion, and financial milestones from the Cantor Healthcare Conference.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/09/25 | 2.38 | 2.60 | 2.35 | 2.56 | 8,625,632 |
24/09/25 | 2.49 | 2.505 | 2.41 | 2.43 | 4,775,648 |
23/09/25 | 2.47 | 2.52 | 2.44 | 2.48 | 6,588,656 |
22/09/25 | 2.66 | 2.66 | 2.4731 | 2.51 | 7,788,180 |
19/09/25 | 2.83 | 2.9399 | 2.65 | 2.66 | 10,733,942 |
18/09/25 | 2.76 | 2.80 | 2.69 | 2.75 | 6,312,800 |
17/09/25 | 2.80 | 2.8494 | 2.694 | 2.72 | 4,948,806 |
16/09/25 | 2.79 | 2.82 | 2.70 | 2.77 | 4,896,830 |
15/09/25 | 2.87 | 2.895 | 2.77 | 2.78 | 5,433,921 |
12/09/25 | 2.77 | 2.89 | 2.73 | 2.84 | 4,550,594 |
|
|
||||
|
|
||||
|
|